Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005463
Status:
COMPLETED
Last Update Posted:
2016-02-18
First Post:
2000-05-25
Brief Title:
Population-Based Modeling of Cholesterol Lowering in the United States
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Heart Lung and Blood Institute NHLBI
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2002-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the cost-effectiveness of cholesterol-lowering strategies in the United States population The study used the Coronary Heart Disease CHD Policy Model a state-transition computer simulation model used to obtain forecasts of the public health impact and economic cost of CHD in the United States population
Detailed Description:
BACKGROUND
The study was part of an Institute-initiated Request for Applications RFA titled Cost-Effective Strategies of Cholesterol-Lowering released by the NHLBI in 1990 The RFA was stimulated by the controversy concerning costs and cost-effectiveness that followed the 1987 report of the National Cholesterol Education Program NCEP Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults The RFA was intended to support a broad and thorough quantitative exploration of the potential health benefits and costs of cholesterol-lowering from multiple perspectives
DESIGN NARRATIVE
The study added to the CHD Policy Model the capability to model the consequences of reductions in LDL cholesterol and increases in HDLLDL ratios in the United States population The CHD Policy Model was used for several studies including to compare the implications of using alternative epidemiologic studies as the basis for estimating the association between cholesterol levels and CHD risk to derive cutting points for initiating cholesterol reduction specific to age sex and CHD risk factors and based on cost-effectiveness criteria to compare the cost-effectiveness of specific targeted and population-wide strategies for cholesterol reduction to incorporate the effects of treatments on quality of life including both adverse effects of cholesterol-lowering drugs and reductions in CHD morbid events and finally to perform a cost-effectiveness analysis of cholesterol screening incorporating costs of screening effects of measurement error on misclassification of patients and variations in individual cholesterol levels over time
The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System PRS record
The study was part of an Institute-initiated Request for Applications RFA titled Cost-Effective Strategies of Cholesterol-Lowering released by the NHLBI in 1990 The RFA was stimulated by the controversy concerning costs and cost-effectiveness that followed the 1987 report of the National Cholesterol Education Program NCEP Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults The RFA was intended to support a broad and thorough quantitative exploration of the potential health benefits and costs of cholesterol-lowering from multiple perspectives
DESIGN NARRATIVE
The study added to the CHD Policy Model the capability to model the consequences of reductions in LDL cholesterol and increases in HDLLDL ratios in the United States population The CHD Policy Model was used for several studies including to compare the implications of using alternative epidemiologic studies as the basis for estimating the association between cholesterol levels and CHD risk to derive cutting points for initiating cholesterol reduction specific to age sex and CHD risk factors and based on cost-effectiveness criteria to compare the cost-effectiveness of specific targeted and population-wide strategies for cholesterol reduction to incorporate the effects of treatments on quality of life including both adverse effects of cholesterol-lowering drugs and reductions in CHD morbid events and finally to perform a cost-effectiveness analysis of cholesterol screening incorporating costs of screening effects of measurement error on misclassification of patients and variations in individual cholesterol levels over time
The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System PRS record
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL046315 | NIH | None | httpsreporternihgovquickSearchR01HL046315 |